Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
28 hedge funds and large institutions have $8.12M invested in Medicenna Therapeutics Corp. Common Shares in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
50% more capital invested
Capital invested by funds: $5.41M → $8.12M (+$2.7M)
47% more funds holding
Funds holding: 19 → 28 (+9)
9.06% more ownership
Funds ownership: 8.33% → 17.39% (+9.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.78M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.13M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$745K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$734K |
| 5 |
EAM
Empery Asset Management
New York
|
+$665K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$226K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$30.5K |
| 3 |
Millennium Management
New York
|
-$4.73K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
MDNA Hedge Fund Activity: Q3 2022 in Review
28 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q3 2022, worth a combined $8.12M — up 50% from $5.41M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MDNA positions and 1 closed out — a net gain of 9 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $1.78M. The largest seller was Morgan Stanley, cutting an estimated $226K.
- 28 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q3 2022, up from 19 in Q2 2022.
- Funds reported $8.12M of Medicenna Therapeutics Corp. Common Shares stock for Q3 2022, up 50% quarter-over-quarter.
- 10 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q3 2022 and 1 closed out, a net change of +9 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q3 2022 was AIGH Capital Management, an estimated $1.78M added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q3 2022 was Morgan Stanley, an estimated $226K sold.
Based on aggregated 13F filings for Q3 2022.